Onderneming Glenmark Life Sciences Limited Bombay S.E.
Aandelen
GLS
INE03Q201024
Farmaceutische producten
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
813,9 INR | +8,21% | +1,43% | +23,86% |
Vakgebied
Aantal werknemers: 1 824
Verkoop per activiteit
INR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Generic
93,0
%
| 19 154 | 90,2 % | 20 099 | 93,0 % | +4,93% |
CDMO
7,0
%
| 1 720 | 8,1 % | 1 513 | 7,0 % | -12,05% |
Verkoop per regio
INR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
India
52,4
%
| 21 232 | 100,0 % | 11 330 | 52,4 % | -46,64% |
International
47,6
%
| - | - | 10 282 | 47,6 % | - |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Yasir Rawjee
CEO | Chief Executive Officer | 58 | 13-08-19 |
Director of Finance/CFO | - | 01-06-22 | |
Compliance Officer | - | 23-02-21 | |
Chief Tech/Sci/R&D Officer | - | 14-07-20 | |
Vinod Naik
BRD | Director/Board Member | - | 12-03-20 |
Mathew George
LAW | General Counsel | - | 01-10-19 |
Sumantra Mitra
HRO | Human Resources Officer | 49 | 11-10-18 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Manju Agarwal
BRD | Director/Board Member | 66 | 30-10-20 |
Yasir Rawjee
CEO | Chief Executive Officer | 58 | 13-08-19 |
Sumantra Mitra
HRO | Human Resources Officer | 49 | 11-10-18 |
Director/Board Member | 64 | 08-01-21 | |
Vinod Naik
BRD | Director/Board Member | - | 12-03-20 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 122 527 172 | 19 263 516 ( 15,72 %) | 0 | 15,72 % |
Bedrijfsgegevens
Glenmark Life Sciences Ltd.
4th Floor, OIA House 470 Cardinal Gracious Road
400099, Mumbai
+91 22 6829 7979
http://www.glenmarklifesciences.comSector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
Kwartaalomzet - Afwijkingspercentage
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 661 mld. | |
+27,00% | 566 mld. | |
-6,76% | 352 mld. | |
+20,34% | 332 mld. | |
+3,00% | 283 mld. | |
+13,09% | 231 mld. | |
+5,46% | 200 mld. | |
-9,61% | 195 mld. | |
-6,26% | 145 mld. |